The first Chinese mpox vaccine has been approved for clinical trials across China starting on September 9, with the company behind it saying that early studies show promising results and effective immunity protection against the highly infectious virus. The jab was developed by Shanghai Institute of Biological Products, a subsidiary of Chinese state-owned pharmaceutical giant...
Unlock this article with Premium. To access all premium content, contact us at [email protected]
Already a member? Log in here
